1409-4142 1409-4142 S1409-41422025000200005 10.63885/rcc.v27s1.002 Costa Rica Nicaragua República Dominicana El Salvador Costa Rica Honduras Costa Rica Panamá Guatemala Panamá Guatemala El Salvador 00 06 2025 00 06 2025 27 5 25

1 2020 41 407-77 2 2024 45 3415-537 3 2023 148 e9-e119 4 2017 33 1041-59 5 2017 38 2565-8 6 2000 53 91-109 7 2007 60 543-7 8 2018 25 116-23 9 2020 382 1395-407 10 2007 30 505-10 11 2016 36 96-105 12 2000 53 783-90 13 2016 80 178-82 14 2008 78 195-209 15 2012 367 991-1001 16 2009 360 213-24 17 2010 18 2014 64 1641-54 19 2016 68 2247-55 20 2017 10 1361-70 21 2011 32 1465-71 22 2014 7 868-74 23 2015 169 663-73 24 2023 52 4-19 25 1991 325 849-53 26 2014 7 593-604 27 2021 13 2134-44 28 2007 147 821 29 2009 2 404-11 30 2019 4 256 31 2017 2 400 32 2012 12 8-11 33 2012 34 2021 23 55 35 2018 137 2166-78 36 2021 78 1919-29 37 2020 23 422-9 38 1996 50 245-51 39 2009 157 988-94 40 2005 55 838-45 41 2003 289 3106 42 Centers for Medicare and Medicaid Services Centers for Medicare and Medicaid Services Centers for Medicare and Medicaid Services 2017 7 43 2021 44 2020 110 S219-21 45 2019 58 719-45 46 2021 77 62-8 47 2018 178 1635-43 48 2021 13 2157-60 49 2010 121 750-8 50 2014 113 1933-40 51 2008 168 2194 52 2008 156 292-300 53 2003 290 86 54 2018 25 1864-72 55 2018 121 143-8 56 2017 70 1689-700 57 2016 58 2016 23 1914-39 59 2015 36 1519-28 60 2010 122 406-41 61 2013 20 620-40 62 2011 31 273-81 63 2008 371 1999-2012 64 2010 60 40-6 65 2015 66 2014 129 28-41 67 2021 7 97-106 68 2015 22 1185-99 69 2016 102 1953-6 70 2014 15 168-75 71 2015 72 2018 391 427-8 73 2018 391 426-7 74 2015 28 424-6 75 2015 13 593-6 76 2005 352 1425-35 77 2010 376 1670-81 78 Cholesterol Treatment Trialists’ Collaboration 2019 393 407-15 79 1994 344 1383-9 80 1996 335 1001-9 81 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group 1998 339 1349-57 82 1997 336 153-62 83 Heart Protection Study Collaborative Group 2002 360 23-33 84 2020 125 874-9 85 2022 135 603-6 86 2016 2 212-7 87 2010 341 88 2010 363 2015-26 89 2021 143 528-39 90 1998 ^s19 Suppl ^s19 Suppl 19 Suppl J52-5 91 2000 342 145-53 92 2009 338 b1665 93 2015 373 2103-16 94 2004 364 849-57 95 2007 167 1720-8 96 1999 341 1097-105 97 2010 121 230-6 98 2010 170 1293-301 99 2006 296 79-86 100 2018 3 280-7 101 2018 320 1172-91 102 2014 312 1779-91 103 2007 298 2507-16 104 2010 11 202-21 105 2021 384 989-1002 106 2015 373 11-22 107 2022 327 138-50 108 2018 392 637-49 109 2005 80 1157-62 110 2012 307 56-65 111 2021 143 1468-80 112 2010 363 905-17 113 2021 143 e984-e1010 114 1998 338 1650-6 115 2002 347 305-13 116 2020 141 90-9 117 2021 42 1203-12 118 2019 381 2497-505 119 2020 383 1838-47 120 2022 28 1916-25 121 2002 324 71-86 122 123 2021 384 1981-90 124 2015 385 2371-82 125 2014 64 2086-97 126 2012 125 505-13 127 2015 36 1252-63 128 2006 354 1706-17 129 1992 340 1421-5 130 2001 357 1385-90 131 2021 7 475-82 132 2002 106 2194-9 133 1999 353 2001-7 134 1995 92 212-8 135 2001 344 1659-67 136 2003 362 7-13 137 2002 143 301-7 138 2014 127 939-53 139 OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) Investigators 2021 10 140 2020 41 3521-9 141 2015 68 585-91 142 2017 69 2710-20 143 2021 42 907-14 144 2021 14 145 2019 5 12-20 146 2014 7 872-81 147 2012 308 1340-9 148 2016 9 1639-48 149 2017 24 91-6 150 2005 58 198-216 151 2014 29 153-63 152 2021 5 727-41 153 2007 356 1503-16 154 1997 50 6-14 155 2006 13 137-49 156 2019 40 13-8